Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations.
Journal
Analytical cellular pathology (Amsterdam)
ISSN: 2210-7185
Titre abrégé: Anal Cell Pathol (Amst)
Pays: United States
ID NLM: 101541993
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
08
2021
accepted:
18
05
2022
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
29
6
2022
Statut:
epublish
Résumé
Gliosarcoma (GSM), a histologic variant of glioblastoma (GBM), carries a poor prognosis with less than one year of median survival. Though GSM is similar with GBM in most clinical and pathological symptoms, GBM has unique molecular and histological features. However, as the rarity of GSM samples, the genetic information of this tumor is still lacking. Here, we take a comprehensive analysis of DNA copy number variations (CNV) in GBM and GSM. Whole genome sequencing was performed on 21 cases of GBM and 15 cases of GSM. CNVKIT is used for CNV calling. Our data showed that chromosomes 7, 8, 9, and 10 were the regions where CNV frequently happened in both GBM and GSM. There was a distinct CNV signal in chromosome 2 especially in GSM. The pathway enrichment of genes with CNV was suggested that the GBM and GSM shared the similar mechanism of tumor development. However, the CNV of some screened genes displayed a disparate form between GBM and GSM, such as AMP, BEND2, HDAC6, FOXP3, ZBTB33, TFE3, and VEGFD. It meant that GSM was a distinct subgroup possessing typical biomarkers. The pathways and copy number alterations detected in this study may represent key drivers in gliosarcoma oncogenesis and may provide a starting point toward targeted oncologic analysis with therapeutic potential.
Identifiants
pubmed: 35757013
doi: 10.1155/2022/2376288
pmc: PMC9226978
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2376288Informations de copyright
Copyright © 2022 Chuan-dong Cheng et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
J Biol Chem. 1998 May 29;273(22):13375-8
pubmed: 9593664
Am J Pathol. 2000 Feb;156(2):425-32
pubmed: 10666371
Neuro Oncol. 2021 Aug 2;23(8):1215-1217
pubmed: 34185090
Perm J. 2008 Fall;12(4):45-8
pubmed: 21339920
J Neurooncol. 2010 Feb;96(3):313-20
pubmed: 19618114
Brain Pathol. 2016 Jul;26(4):517-22
pubmed: 26443480
Atherosclerosis. 2018 Apr;271:182-192
pubmed: 29524861
Pharmaceuticals (Basel). 2021 Jun 27;14(7):
pubmed: 34198978
Genes Chromosomes Cancer. 2002 Aug;34(4):416-27
pubmed: 12112531
Oncotarget. 2017 Jan 24;8(4):6085-6101
pubmed: 28030832
J Neurooncol. 2019 Jul;143(3):381-392
pubmed: 31073965
Nat Chem Biol. 2016 Sep;12(9):748-54
pubmed: 27454931
J Exp Clin Cancer Res. 2015 Jan 22;34:4
pubmed: 25609158
J Biol Chem. 2000 Oct 27;275(43):33205-8
pubmed: 10973944
J Gastrointest Surg. 2016 Dec;20(12):2074-2082
pubmed: 27730400
Exp Mol Med. 2017 Apr 14;49(4):e317
pubmed: 28408749
Brain Pathol. 2004 Apr;14(2):131-6
pubmed: 15193025
Mol Cell Biol. 1994 Jan;14(1):641-5
pubmed: 8264632
J Neurosurg. 1998 Sep;89(3):425-30
pubmed: 9724117
Am J Pathol. 2007 May;170(5):1445-53
pubmed: 17456751
J Clin Invest. 2017 Apr 3;127(4):1353-1369
pubmed: 28287402
Front Oncol. 2015 Jan 29;5:5
pubmed: 25688333
Genes Dev. 1998 Oct 1;12(19):3084-95
pubmed: 9765209
Clin Epigenetics. 2019 Aug 5;11(1):114
pubmed: 31383000
Cancers (Basel). 2021 Apr 26;13(9):
pubmed: 33925821
Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4
pubmed: 8864278
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931